Latest Pharma Insights
Q&A: Proposed US Sunscreen Monograph Addition Shines Light On Questions As Well As Opportunities
“Our sense is that companies are currently focused on timing, scope and execution. For example, knowing when a final order might issue … We also imagine that formulators are scrutinizing the proposed list of permitted combinations, the 6% cap, and the permitted dosage forms,” say ArentFox Schiff att
HBW Insight - January 15, 2026
“Our sense is that companies are currently focused on timing, scope and execution. For example, knowing when a final order might issue … We also imagine that formulators are scrutinizing the proposed list of permitted combinations, the 6% cap, and the permitted dosage forms,” say ArentFox Schiff att
HBW Insight - January 15, 2026
Optimism Reigns At J.P. Morgan Despite A Lack Of Deals
The mood in San Francisco was focused and upbeat as investors and dealmakers continue to anticipate a busy year ahead for M&A.
Scrip - January 15, 2026
The mood in San Francisco was focused and upbeat as investors and dealmakers continue to anticipate a busy year ahead for M&A.
Scrip - January 15, 2026
J.P. Morgan Notebook: Big Pharmas Weigh In On Vaccines, AI And MFN
Sanofi's Paul Hudson on vaccine M&A, BMS's Lenkowsky on its MFN deal, Gilead's business development priorities, BI prepares for obesity/MASH readouts, GSK talks AI and AstraZeneca buys Modella AI, plus more from day three of J.P. Morgan.
Scrip - January 15, 2026
Sanofi's Paul Hudson on vaccine M&A, BMS's Lenkowsky on its MFN deal, Gilead's business development priorities, BI prepares for obesity/MASH readouts, GSK talks AI and AstraZeneca buys Modella AI, plus more from day three of J.P. Morgan.
Scrip - January 15, 2026
Optimism Reigns At J.P. Morgan Despite A Lack Of Deals
The mood in San Francisco was focused and upbeat as investors and dealmakers continue to anticipate a busy year ahead for M&A.
Scrip - January 15, 2026
The mood in San Francisco was focused and upbeat as investors and dealmakers continue to anticipate a busy year ahead for M&A.
Scrip - January 15, 2026
J.P. Morgan Notebook: Big Pharmas Weigh In On Vaccines, AI And MFN
Sanofi's Paul Hudson on vaccine M&A, BMS's Lenkowsky on its MFN deal, Gilead's business development priorities, BI prepares for obesity/MASH readouts, GSK talks AI and AstraZeneca buys Modella AI, plus more from day three of J.P. Morgan.
Scrip - January 15, 2026
Sanofi's Paul Hudson on vaccine M&A, BMS's Lenkowsky on its MFN deal, Gilead's business development priorities, BI prepares for obesity/MASH readouts, GSK talks AI and AstraZeneca buys Modella AI, plus more from day three of J.P. Morgan.
Scrip - January 15, 2026
UK Wary Of Complexities After EU ‘Unjams’ MDR
The UK MHRA will soon consult on allowing CE-marked devices indefinite access to the Great Britain market. Meanwhile, the EU has at last moved to make the MDR/IVDR more user friendly. Taylor Wessing partner Alison Dennis reflects on how these events could influence evolving UK medtech legislation.
Medtech Insight - January 14, 2026
The UK MHRA will soon consult on allowing CE-marked devices indefinite access to the Great Britain market. Meanwhile, the EU has at last moved to make the MDR/IVDR more user friendly. Taylor Wessing partner Alison Dennis reflects on how these events could influence evolving UK medtech legislation.
Medtech Insight - January 14, 2026
Blood, Games, BrainMRI – NeuroAge Gives You Tools To Reprogram Brain Age, Reduce Alzheimer’s Risk
MIT-scientist turned entrepreneur Christin Glorioso founded start-up NeuroAge Therapeutics to reverse brain aging and fight dementia.
Medtech Insight - January 14, 2026
MIT-scientist turned entrepreneur Christin Glorioso founded start-up NeuroAge Therapeutics to reverse brain aging and fight dementia.
Medtech Insight - January 14, 2026
J&J Maps Robotics Growth Arc In 2028 As Ottava, Monarch Near Key Regulatory Milestones
Johnson & Johnson expects a planned orthopedics separation to unfold over time, with a potential spin-off in the second half of 2027, drawing on experience from its earlier consumer health carve-out to guide execution.
Medtech Insight - January 14, 2026
Johnson & Johnson expects a planned orthopedics separation to unfold over time, with a potential spin-off in the second half of 2027, drawing on experience from its earlier consumer health carve-out to guide execution.
Medtech Insight - January 14, 2026
Medtech 2026: Collaboration, Coverage Improvements Top Industry Wish Lists
Wishes for 2026 from our medtech experts focused on value-based care, faster reimbursements, and better collaboration. Key ideas included enhancing patient engagement, reducing waste, and aligning coverage policies to improve health outcomes and innovation.
Medtech Insight - January 14, 2026
Wishes for 2026 from our medtech experts focused on value-based care, faster reimbursements, and better collaboration. Key ideas included enhancing patient engagement, reducing waste, and aligning coverage policies to improve health outcomes and innovation.
Medtech Insight - January 14, 2026
Medtech 2026: AI Shows Patient Care Potential, But Regulation Remains Tricky
AI in medtech offers exciting potential for improving patient care and operational efficiency, but faces significant regulatory challenges. Ensuring data quality and building trust among users are essential for successful AI integration in healthcare, our expert panel said.
Medtech Insight - January 14, 2026
AI in medtech offers exciting potential for improving patient care and operational efficiency, but faces significant regulatory challenges. Ensuring data quality and building trust among users are essential for successful AI integration in healthcare, our expert panel said.
Medtech Insight - January 14, 2026
Q&A: Proposed US Sunscreen Monograph Addition Shines Light On Questions As Well As Opportunities
“Our sense is that companies are currently focused on timing, scope and execution. For example, knowing when a final order might issue … We also imagine that formulators are scrutinizing the proposed list of permitted combinations, the 6% cap, and the permitted dosage forms,” say ArentFox Schiff att
HBW Insight - January 15, 2026
“Our sense is that companies are currently focused on timing, scope and execution. For example, knowing when a final order might issue … We also imagine that formulators are scrutinizing the proposed list of permitted combinations, the 6% cap, and the permitted dosage forms,” say ArentFox Schiff att
HBW Insight - January 15, 2026
Allos Raises $5m For AI-Driven Complex Generic Reformulation Platform
Oxford-based Allos is scaling up its AI platform, which aims to revive investments into reformulating complex generics.
Generics Bulletin - January 14, 2026
Oxford-based Allos is scaling up its AI platform, which aims to revive investments into reformulating complex generics.
Generics Bulletin - January 14, 2026
J.P. Morgan: Teva Targets Long-Term Value Over Fast Uptake For Long-Acting Olanzapine
Management says it is prepared to sacrifice early volume if pricing fails to reflect the drug’s role in moderate to severe schizophrenia.
Generics Bulletin - January 14, 2026
Management says it is prepared to sacrifice early volume if pricing fails to reflect the drug’s role in moderate to severe schizophrenia.
Generics Bulletin - January 14, 2026
Amphastar Expands Peptide Push With Synthetic Corticotropin Licensing Agreement
Amphastar is looking to a “strategically important addition to our growing proprietary peptide portfolio,” after striking an exclusive licensing agreement with China-based Nanjing Hanxin Pharmaceutical Technology.
Generics Bulletin - January 14, 2026
Amphastar is looking to a “strategically important addition to our growing proprietary peptide portfolio,” after striking an exclusive licensing agreement with China-based Nanjing Hanxin Pharmaceutical Technology.
Generics Bulletin - January 14, 2026
Building Companies Like Experiments: The Flagship Pioneering Model
From biotech experiments to billion-dollar breakthroughs, Noubar Afeyan has built a career out of turning bold ideas into transformative companies.
In Vivo - January 14, 2026
From biotech experiments to billion-dollar breakthroughs, Noubar Afeyan has built a career out of turning bold ideas into transformative companies.
In Vivo - January 14, 2026
The Challenge Of Measuring Almost Nothing: HER2 Testing Enters Ultralow Era
Enhertu's approval for ever-lower levels of HER2 expression is pushing standard immunohistochemistry assays beyond their limits. Pathologists say they have a solution.
In Vivo - January 14, 2026
Enhertu's approval for ever-lower levels of HER2 expression is pushing standard immunohistochemistry assays beyond their limits. Pathologists say they have a solution.
In Vivo - January 14, 2026